Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RPA1 | P27694 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ESRRA | P11474 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1999127 | 1.00 | GRM5 (0.50) | GRM5GAAKDM4EPOLBRXRA | |
| SCHEMBL2893769 | 0.88 | GRM5 (0.50) | GRM5GAAKDM4EPOLBMEN1 | |
| SCHEMBL2893766 | 0.88 | GRM5 (0.50) | GRM5GAAKDM4EPOLBMEN1 | |
| SCHEMBL2889925 | 0.80 | GRM5 (0.50) | GRM5GAALMNATP53MAPT | |
| SCHEMBL3103976 | 0.80 | GRM5 (0.50) | GRM5GAALMNATP53MAPT | |
| SCHEMBL3115514 | 0.80 | GRM5 (0.46) | GRM5GAAMEN1KMT2ALMNA | |
| SCHEMBL2001185 | 0.80 | GRM5 (0.46) | GRM5GAAMEN1KMT2ALMNA | |
| SCHEMBL2002209 | 0.80 | GRM5 (0.46) | GRM5GAAMEN1KMT2ALMNA | |
| SCHEMBL1996494 | 0.74 | GRM5 (0.43) | GRM5GAARXRAGRIN1GRIN2B | |
| SCHEMBL2893686 | 0.72 | GRM5 (0.42) | GRM5KDM4EMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079730-A1 | MGLUR5 MODULATORS | Astra Zeneca AB (SE) | 2009-07-22 | — | — | EP | claimed |
| US-20090131454-A1 | New compounds 067 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | claimed |
| US-20090111857-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | claimed |
| US-20080125436-A1 | 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting | ASTRAZENECA AB (SE) | 2008-05-29 | — | — | US | claimed |
| WO-2008041075-A1 | MGLUR5 MODULATORS | ASTRAZENECA AB (SE) | 2008-04-10 | — | — | WO | claimed |
| US-7960422-B2 | Pharmaceutically active compounds containing tetrazolyl and triazolyl rings | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-7772235-B2 | mGluR5 modulators | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-20090131454-A1 | New compounds 067 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090111857-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20080125436-A1 | 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting | ASTRAZENECA AB (SE) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111857-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM1 | GRM5 1/4885GAA 3821/4885KDM4E 916/4885 |
| US-20090131454-A1 | New compounds 067 | UGT2B7, UGT1A7, CYP3A7 | GRM5 1146/4885GAA 188/4885KDM4E 3734/4885 |
| US-20080125436-A1 | 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting | GLRA1, GRM1, GRM5 | GRM5 3/4885GAA 2892/4885KDM4E 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.